MiR-122 could not only adverse to cisplatin resistance in cisplatin-treated HepG2 cells [34], but also make HCC cells re-sensitize to adriamycin (ADM) and vincristine by down-regulating MDR related genes, such as MDR-1, MRP, GST-pi [35]. The gene discussed is ABCC1; the disease is hepatocellular carcinoma.